Stockscreener 앱 받기
17.11
0.82%
0.14
시간 외 거래:
17.11
전일 마감가:
$16.97
열려 있는:
$17
하루 거래량:
179.51K
Relative Volume:
0.99
시가총액:
$583.34M
수익:
$99.53M
순이익/손실:
$-21.57M
주가수익비율:
-26.37
EPS:
-0.6488
순현금흐름:
$-9.84M
1주 성능:
+6.01%
1개월 성능:
+8.91%
6개월 성능:
+2.27%
1년 성능:
+68.24%
1일 변동 폭
$16.54
$17.38
1주일 범위
$16.24
$18.23
52주 변동 폭
$7.5625
$19.60
뉴로페이스 Stock (NPCE) Company Profile
명칭
Neuropace Inc
전화
(650) 237-2700
주소
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
17.11 | 583.34M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
뉴로페이스 Stock (NPCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-03-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 개시 | Leerink Partners | Outperform |
| 2023-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 개시 | Lake Street | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 개시 | Robert W. Baird | Outperform |
| 2021-05-17 | 개시 | JP Morgan | Overweight |
| 2021-05-17 | 개시 | Morgan Stanley | Overweight |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 개시 | Wells Fargo | Overweight |
모두보기
뉴로페이스 주식(NPCE)의 최신 뉴스
NeuroPace (NPCE) Proxy filing Summary - Quartr
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NeuroPace (NASDAQ:NPCE) Stock Price Up 1.1%What's Next? - MarketBeat
NeuroPace Inc offers free webinar on RNS System for epilepsy patients - Traders Union
(NPCE) Volatility Zones as Tactical Triggers - Stock Traders Daily
At US$17.80, Is It Time To Put NeuroPace, Inc. (NASDAQ:NPCE) On Your Watch List? - simplywall.st
DHR Health pioneers responsive neurostimulation therapy with NeuroPace Inc RNS System in Texas - Traders Union
Neuropace Inc. (NPCE) Q1 2026 Earnings: EPS Surpasses Estimates, Shares GainInvestor Earnings Call - dars.gov.et
Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN
Price to earnings forward of Neuropace, Inc. – NASDAQ:NPCE - TradingView
NPCENeuroPace Inc Website Traffic and Mobile Apps Usage - Finviz
NeuroPace | 4: Statement of changes in beneficial ownership of securities-Director Fischer Frank M - Moomoo
NeuroPace Inc patients see 62 percent median seizure reduction at six months in largest FDA-reviewed study - Traders Union
Price-Driven Insight from (NPCE) for Rule-Based Strategy - Stock Traders Daily
FDA Approves NeuroPace AI Driven Feature For Epilepsy Care - HarianBasis.co
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™ - Insider Monkey
NeuroPace, Inc. Actuals & Estimates (NASDAQ:NPCE) - TradingView
NeuroPace (NPCE) CMO has shares withheld to cover RSU tax bill - Stock Titan
NPCE Forecast — Price Target — Prediction for 2027 - TradingView
Neuropace Inc (NPCE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuropace Inc (NPCE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuropace Inc. (NPCE) Gains on Rising Volume: Support Holds Above $15Fibonacci Extension - dars.gov.et
Form 4 Neuropace Inc For: 22 June By Investing.com - Investing.com Nigeria
[Form 4] NeuroPace Inc Insider Trading Activity - Stock Titan
NeuroPace (NPCE) director granted 789 shares as quarterly fee award - Stock Titan
NeuroPace | 4: Statement of changes in beneficial ownership of securities-Director Kumar Rakhi - Moomoo
NeuroPace (NPCE) director Rakhi Kumar awarded 989 shares as quarterly retainer - Stock Titan
NeuroPace | 4: Statement of changes in beneficial ownership of securities-Director Geiger Uri - Moomoo
NeuroPace, Inc.(NasdaqGM:NPCE) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
Neuropace Inc (NPCE) Institutional Confidence - TradingKey
Neuropace Inc (NPCE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuropace Inc (NPCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuropace Inc (NPCE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuropace Inc (NPCE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade - MSN
(NPCE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
NeuroPace (NPCE) down 0.6% since last earnings report: Can it rebound? - MSN
NeuroPace Inc RNS System gains favor for targeted seizure interruption - Traders Union
Here's why you should add NeuroPace stock to your portfolio now - MSN
NPCE Explains How NeuroPace's RNS System Makes Money - MSN
NeuroPace Stock Draws Focus As RNS Adoption Expands - Kalkine Media
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - Yahoo Finance
NeuroPace, Inc. Files Form 8-K Reporting 2026 Annual Meeting Results and Company Information - Minichart
NeuroPace shareholders elect directors and ratify auditor at annual meeting By Investing.com - Investing.com South Africa
NeuroPace shareholders elect directors and ratify auditor at annual meeting - Investing.com
NeuroPace Shareholders Approve Directors and Auditor at Meeting - TipRanks
NeuroPace (NASDAQ: NPCE) investors back board slate and PwC at 2026 meeting - Stock Titan
뉴로페이스 (NPCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
자본화:
|
볼륨(24시간):